NovoSorb® BTM

PolyNovo Limited
ABN 96 083 866 862

2/320 Lorimer Street
Port Melbourne
VIC Australia 3207

P +61 (0) 3 8681 4050
F +61 (0) 3 8681 4099

12 September 2025

ASX Announcement

NovoSorb BTM accelerates healing of large post-surgical diabetes-related foot wounds

PolyNovo Limited **(PolyNovo or the Company)** is pleased to announce the results of a post-market investigator-initiated randomised controlled trial (RCT) for post-surgical diabetes-related foot wounds **(Chronic Wound Study)**. The results will be showcased in a podium presentation at the Australian & New Zealand Society of Vascular Surgery conference, in Adelaide from 2 to 5 October 2025.

The study was started in April 2022 and announced in our Annual Reports from 2022 to 2025.

This study of subjects with neuroischemic diabetic foot wounds compares the use of NovoSorb BTM combined with negative pressure wound therapy (NPWT) to the standard of care (SOC) consisting of NPWT alone. Between May 2022 and September 2024, a total of 64 participants were enrolled, 32 with NovoSorb BTM and NPWT, and 30 to SOC. (1 assigned to NovoSorb BTM and NPWT did not progress to treatment, 1 SOC withdrew).

Study results

- Interim analysis of complete wound healing in all wounds at 12 months was observed in 66.7% of NovoSorb BTM-treated wounds compared with 56.5 % of SOC; however, this was not statistically significant (P = 0.48).
- Subanalysis showed a significant decrease in the mean time to complete healing of wounds > 10cm2 in the NovoSorb BTM group (191 days) compared with the SOC group (319 days).
- There was no significant difference observed in 12-month amputation rates.

Study conclusion

The study concludes that large surface area wounds (> 10cm^2) treated with NovoSorb BTM achieved significantly faster wound closure when compared with the SOC, positioning NovoSorb BTM as a useful device in the limited treatment options for post-surgical diabetes-related neuropathic / neuroischemic wounds.

Acting Chief Executive Officer, Dr Robyn Elliott said: "*The exciting results of this study support the growing body of evidence that the NovoSorb platform products are a significant addition to the treatment regime for diabetic related wounds and ulcers. A decrease of "time to complete healing" of over 4 months is a huge benefit to the patient and health care system."*

Chairman, David Williams said: "*I am excited about these results because this is likely to be important evidence for outpatient adoption and treatment in the U.S. if CMS pricing changes on 1 January 2026.*"

This announcement has been authorised by Company Secretary Jan Gielen.

About the Chronic Would Study

An RCT comparing the use of NovoSorb BTM in conjunction with NPWT in the treatment of moderate to severe post-surgical diabetes-related foot wounds, compared with the NPWT alone (SOC). NPWT was used for a minimum of 14 days in both groups, with wounds healing by secondary intention (not skin grafted).

Participant inclusion was limited to wounds of moderate-to-high severity as defined by SVS Wound, Ischemia and foot Infection (WIfI) grading system (grade 3 or 4). Primary outcomes were complete wound healing at 12 weeks, and amputation rates at 12-month post treatment. Secondary outcomes included days to wound healing, wound surface area reduction, and infection.

About PolyNovo®

PolyNovo is a disruptive medical technology company, based in Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. After treating 84,000+ patients across 46 countries, the company is investing for growth with new products, indications, and markets. For more information see polynovo.com.

About NovoSorb®

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.